Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic
pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real …

Background and objective Multiple randomized controlled studies have shown that
pirfenidone and nintedanib are effective and safe for treating idiopathic pulmonary fibrosis …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Extract The antifibrotic medications pirfenidone and nintedanib became the first US Food
and Drug Administration (FDA)-approved medical therapy for the treatment of idiopathic …

Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the
treatment IPF. Prior to being approved for use in England for patients with FVC> 50% and< …

Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …

Background Pirfenidone and nintedanib are the sole pharmacological therapies currently
approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in …

The primary objective of the study is to evaluate the safety and tolerability of combined
pirfenidone and nintedanib after 24 Methods: weeks in 80 patients (NCT02598193). This pre …

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg· day− 1)
and nintedanib (200–300 mg· day− 1) in patients with idiopathic pulmonary fibrosis (IPF) …

Background The antifibrotic drugs nintedanib and pirfenidone reduce disease progression
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …